First-of-its-Kind skin treatment trial offers hope for rare genetic disorder
NCT ID NCT06137157
Summary
This is the first time a new topical ointment called ATR12-351 is being tested in people. The study aims to see if it is safe and well-tolerated in about 12 adults with Netherton Syndrome, a rare and severe genetic skin condition. The ointment is designed to address the root cause of the disease by replacing a missing protein in the skin. Each participant will apply the ointment to skin on one side of their body and a placebo cream on the other side twice daily for two weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NETHERTON SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
RECRUITINGPalo Alto, California, 94304, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Yale University
COMPLETEDNew Haven, Connecticut, 06519, United States
Conditions
Explore the condition pages connected to this study.